CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the quarter ended June 30, 2023, provided a corporate update and reiterates upcoming milestones.

Related Keywords

Switzerland ,Houston ,Texas ,United States ,Spain ,France ,Italy ,Jenene Thomas ,John Climaco ,Nasdaq ,Linkedin ,Company On Twitter ,Pharmaceuticals Inc ,Shareholder Intelligence Services ,Facebook ,Securities Exchange ,Exchange Commission ,Data Safety Monitoring Board ,Expected Milestones ,Potentially Pivotal Trial ,Financial Results ,Second Quarter ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,The Company ,Pharmaceuticals ,Clinical Trial ,Interim Analysis ,Rns Pharma ,Company ,Pivotal Study ,